Inactivated Vaccine-Induced SARS-CoV-2 Variant-SpecificImmunity in Children

Vista sencilla de ítem
dc.contributor.authorSoto, Jorge A.
dc.contributor.authorMelo González, Felipe
dc.contributor.authorGutierrez Vera, Cristián
dc.contributor.authorSchultz, Bárbara M.
dc.contributor.authorBerríos Rojas, Roslye V.
dc.contributor.authorRivera Pérez, Daniela
dc.contributor.authorPiña Iturbe, Alejandro
dc.contributor.authorHoppe Elsholz, Guillermo
dc.contributor.authorDuarte, Luisa F.
dc.contributor.authorVázquez, Yaneisi
dc.contributor.authorMoreno Tapia, Daniela
dc.contributor.authorRíos, Mariana
dc.contributor.authorPalacios, Pablo A.
dc.contributor.authorGarcia Betancourt, Richard
dc.contributor.authorSantibañez, Álvaro
dc.contributor.authorPacheco, Gaspar A.
dc.contributor.authorMendez, Constanza
dc.contributor.authorAndrade, Catalina A.
dc.contributor.authorSilva, Pedro H.
dc.contributor.authorDiethelm Varela, Benjamín
dc.contributor.authorAstudillo, Patricia
dc.contributor.authorCalvo, Mario
dc.contributor.authorCárdenas, Antonio
dc.contributor.authorGonzález, Marcela
dc.contributor.authorGoldsack, Macarena
dc.contributor.authorGutiérrez, Valentina
dc.contributor.authorPotin, Marcela
dc.contributor.authorSchilling, Andrea
dc.contributor.authorTapia, Lorena I.
dc.contributor.authorTwele, Loreto
dc.contributor.authorVillena, Rodolfo
dc.contributor.authorGrifoni, Alba
dc.contributor.authorSette, Alessandro
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorFasce, Rodrigo A.
dc.contributor.authorFernández, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamírez, Eugenio
dc.contributor.authorGaete Argel, Aracelly
dc.contributor.authorAcevedo, Mónica L.
dc.contributor.authorValiente Echeverría, Fernando
dc.contributor.authorSoto Rifo, Ricardo
dc.contributor.authorRetamal Díaz, Angello
dc.contributor.authorMuñoz Jofré, Nathalia
dc.contributor.authorPedCoronaVac03CL Study Group
dc.contributor.authorMeng, Xing
dc.contributor.authorXin, Qianqian
dc.contributor.authorAlarcón Bustamante, Eduardo
dc.contributor.authorGonzález Aramundiz, José V.
dc.contributor.authorLe Corre, Nicole
dc.contributor.authorÁlvarez Figueroa, María Javiera
dc.contributor.authorGonzález, Pablo A.
dc.contributor.authorAbarca, Katia
dc.contributor.authorPerret, Cecilia
dc.contributor.authorCarreño, Leandro J.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2025-12-16T12:53:01Z
dc.date.available2025-12-16T12:53:01Z
dc.date.issued2022
dc.description.abstractMultiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD41 T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD41 T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD41 T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials .gov under no. NCT04992260.)
dc.description.sponsorship1. Sinovac Biotech 2. FONDECYT 1190156, Agencia Nacional de Investigación y Desarrollo (ANID). 3. FONDECYT 1211547, Agencia Nacional de Investigación y Desarrollo (ANID). 4. FONDECYT 1190830, Agencia Nacional de Investigación y Desarrollo (ANID). 5. El Instituto Milenio de Inmunología e Inmunoterapia, Programa ICN09_016 (anteriormente P09/016-F) de la ANID-Iniciativa Científica Milenio. 6. El Fondo de Innovación para la Competitividad FIC-R 2017 (código BIP 30488811-0). 7. Instituto Nacional de Alergias y Enfermedades Infecciosas, Institutos Nacionales de Salud, Departamento de Salud y Servicios Humanos, bajo el contrato n.° 75N93021C00016 a A.S. y el contrato n.° 75N93019C00065.
dc.identifier.doi10.1128/mbio.01311-22
dc.identifier.issn2161-2129
dc.identifier.urihttps://repositorioabierto.uantof.cl/handle/uantof/584
dc.language.isoen
dc.publisherAmerican Society for Microbiology
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcemBio
dc.subjectCoronaVac
dc.subjectphase3clinical trial
dc.subjectpediatric
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectvaccines
dc.subjectvariants of concern
dc.subjectimmunogenicity
dc.subjectsafety
dc.titleInactivated Vaccine-Induced SARS-CoV-2 Variant-SpecificImmunity in Children
dc.typeArticle
oaire.citation.issue6
oaire.citation.volume13
organization.identifier.rorhttps://ror.org/04eyc6d95
organization.legalNameUniversidad de Antofagasta
uantof.identificator.departmentDepartamento Ciencias Médicas
uantof.identificator.facultyFacultad de Medicina y Odontología
uantof.identificator.facultyFacultad de Ciencias del Mar y Recursos Biológicos
uantof.identificator.facultyFacultad de Ciencias de la Salud
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
soto-et-al-2022-inactivated-vaccine-induced-sars-cov-2-variant-specific-immunity-in-children.pdf
Tamaño:
2.37 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descripción:
Descargar
Colecciones
Departamento de Ciencias Médicas
Departamento de Biotecnología
Departamento de Tecnología Médica